Gene Vector
Pioneering the future of AAV gene therapy for ophthalmic, neuromuscular, genetic, and metabolic diseases.
est. 2017
Valbiotis
Valbiotis develops nutrition solutions to prevent metabolic diseases and provides support for patients, including Valedia for type 2 diabetes.
57 employees · est. 2014 · La Rochelle, France
Valbiotis is the older company (2017 vs 2014).
Side-by-Side Comparison
| Metric | Gene Vector | Valbiotis |
|---|---|---|
| Founded | ||
| Founded | 2017 | 2014 older |
| Headquarters | ||
| Headquarters | Not tracked yet | La Rochelle, France |
| Employees | ||
| Employees | Not tracked yet | 57 |
| Industry | ||
| Industry | Biotechnology | Biotechnology |
| Funding Stage | ||
| Funding Stage | Series A | Post Ipo Equity |
| Total Funding | ||
| Total Funding | $3.16M | $26.50M |
| Funding Rounds | ||
| Funding Rounds | 2 | 3 |
| Services | ||
| Services | Not tracked yet | Not tracked yet |
| Target Customers | ||
| Target Customers | Not tracked yet | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Gene Therapy, AAV Therapy, Ophthalmic Diseases, Neuromuscular Disorders, Genetic Diseases, Metabolic Diseases, Drug Development, Innovation, Biopharmaceuticals, Pharmaceuticals | Metabolic Diseases, Nutrition Solutions, Type 2 Diabetes, Cardiovascular Diseases, Health Innovation, Clinical Trials, Microbiota, Microbiome, NASH, NAFLD, Blood Pressure, Cholesterol Management, Plant-based Resources, Scientific Innovation, Health Support |
| Website | ||
| Website | jwksw.com | valbiotis.com |
About Gene Vector
Gene Vector is a biotechnology company that is dedicated to advancing the development of novel adeno-associated virus (AAV) gene therapy drugs. Founded in 2017, the company is at the forefront of pioneering the future of AAV gene therapy for ophthalmic, neuromuscular, genetic, and metabolic diseases...
About Valbiotis
Valbiotis is a biotechnology startup based in France, founded in 2014. The company is dedicated to developing nutrition solutions to prevent metabolic diseases and provide support for patients, including Valedia for type 2 diabetes. Valbiotis is committed to scientific innovation for preventing and...
We will tell you when either one moves
BounceWatch watches Gene Vector and Valbiotis for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Gene Vector and Valbiotis — by email.
Frequently Asked Questions
Compare Gene Vector with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Gene Vector on 12 Sep 2024, and Valbiotis on 11 Jun 2025. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.